Unlabelled: We assessed the feasibility and safety of a rota-flush solution with 10,000 U of unfractionated heparin in 1 L of normal saline in patients who underwent rotational atherectomy.
Background: Rotational atherectomy with the Rotablator (Boston Scientific) rotational atherectomy system is an effective way to modify severely calcified plaque. Potential complications include coronary spasm and slow-flow/no-flow. A pressured rota-flush solution is infused into the device to lubricate the drive shaft to minimize the risk of these complications as well as facilitate delivery of the device. RotaGlide lubricant (Boston Scientific), which decreases the friction between the drive shaft and RotaWire (Boston Scientific), is routinely added to the rota-flush solution. Antispasmotic agents including nitroglycerin and verapamil are commonly added to the rota-flush solution, but can lead to hemodynamic disturbances like hypotension and bradycardia.
Methods: A total of 67 consecutive patients who underwent rotational atherectomy from July 2012 to June 2015 were included in this analysis. The primary endpoint was procedural success.
Results: Procedural success was achieved in all patients. Significant hypotension occurred in 6%. No patients developed severe bradycardia requiring emergent insertion of a transvenous pacemaker. Major adverse cardiac and cerebral events occurred in 6.0%, all due to non-fatal myocardial infarction. Slow/no flow occurred in 7%, with subsequent resolution after intracoronary vasodilator therapy. Coronary spasm occurred in 4%. Stent thrombosis, perforation, flow-limiting dissection, and stent loss were not observed.
Conclusion: A rota-flush solution with 10,000 U of unfractionated heparin in 1 L of normal saline is a reasonable alternative to the routinely used solution which includes the RotaGlide lubricant, nitroglycerin, and verapamil.
Download full-text PDF |
Source |
---|
Background: Rotational atherectomy (RA) may cause bradyarrhythmias and transitory atrioventricular block when performed in the right coronary artery (RCA) or a dominant circumflex (CX) coronary artery. However, there are no studies of a solution that can prevent coronary flow deterioration and bradycardia complications that may occur during RA. We aimed to create an alternative rota-flush solution to minimize the risk of bradycardia and complete atrioventricular block (AVB) that can occur during RA.
View Article and Find Full Text PDFCardiol Ther
December 2022
Department of Cardiology, The Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei, No. 17 Lu jiang Road, Hefei, 230001, Anhui, China.
Introduction: This prospective study accessed the feasibility and safety of the heparin rota-flush solution in patients undergoing rotational atherectomy (RA).
Methods: Between August 2019 and November 2021, 200 patients who underwent RA were included in this study, among whom 103 (51.5%) were randomly allocated into the heparin rota-flush group and 97 (48.
Indian Heart J
February 2022
Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, 226003, India. Electronic address:
Cardiovasc Revasc Med
July 2019
Department of Cardiology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Introduction: The efficacy of heparin based flush solutions in rotational atherectomy (RA) has not been validated. Recently, a single center study demonstrated the feasibility of an alternative flush solution with 10,000U of unfractionated heparin (UFH) in 1L of normal saline. We aimed to evaluate the safety and efficacy of an alternative flush solution intermittently utilized at our institution.
View Article and Find Full Text PDFJ Invasive Cardiol
January 2017
100 Medical Plaza Suite 630, Los Angeles, CA 90095 USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!